Abstract
Protein kinase inhibitors (PKIs) represent up-to-date therapeutic approach in breast cancer treatment. Although cancer is a rapidly progressive disease, many substances, including PKIs, are usually used at fixed doses without regard to each patient's individuality. Therapeutic drug monitoring (TDM) is a tool that allows individualization of therapy based on drug plasma levels. For TDM conduct, exposure-response relationships of drug substances are required. The pharmacokinetic data and exposure-response evidence supporting the use of TDM for 6 PKIs used in breast cancer treatment, one of the most common female tumour diseases, are discussed in this review.
Highlights
Breast cancer is considered the most common female cancer disease worldwide (Sancho-Garnier and Colonna, 2019)
One of the recently introduced approaches in breast cancer treatment is the inactivation of protein kinases
Therapeutic drug monitoring (TDM) directly clarifies the actual drug concentration in serum and allows dosing optimization based on simulated pharmacokinetic parameters of either Cmax, Ctrough, or AUC derived from a population pharmacokinetic model and adjusted to individual patients’ characteristics (Herviou et al, 2016)
Summary
Breast cancer is considered the most common female cancer disease worldwide (Sancho-Garnier and Colonna, 2019). TDM directly clarifies the actual drug concentration in serum and allows dosing optimization based on simulated pharmacokinetic parameters of either Cmax, Ctrough, or AUC (area under the curve) derived from a population pharmacokinetic model and adjusted to individual patients’ characteristics (Herviou et al, 2016). This approach could improve anticancer treatment efficacy if there was a suitable and predictive pharmacokinetic (PK) parameter.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
